Elevated levels of extracellular vesicles are associated with therapy failure and disease progression in breast cancer patients undergoing neoadjuvant chemotherapy

• Main Authors: Lisa König, Sabine Kasimir-Bauer, Ann-Kathrin Bittner, Oliver Hoffmann, Bettina Wagner, Luis Felipe Santos Manvailer, Rainer Kimmig, Peter A. Horn, Vera Rebmann
• Format: Article
• Language: English
• Published: Taylor & Francis Group 2018-01-01
• Series: OncoImmunology
• Subjects: breast cancer; extracellular vesicles; circulating tumor cells; neoadjuvant chemotherapy; minimal residual disease
• Online Access: http://dx.doi.org/10.1080/2162402X.2017.1376153

Extracellular vesicles (EVs) have been discussed as a diagnostic tool for minimal residual disease (MRD) evaluation in breast cancer (BC) in addition to the analysis of circulating tumor cells (CTCs). Therefore, we investigated circulating EV levels as surrogate markers for disease monitoring and prediction of prognosis in primary, non-metastatic, locally advanced BC patients. EVs were enriched from blood samples of BC patients before and after neoadjuvant chemotherapy (NACT) and from healthy females. EV marker expression analysis was performed and EV sizes and concentrations were determined by nanoparticle tracking analysis. The results were associated with disease status, outcome and CTC presence, evaluated by gene expression analysis after enrichment. We demonstrated that i) the EV concentration was 40-fold higher in BC patients compared to healthy females, ii) the EV concentration increased during therapy, iii) an increased EV concentration pre-NACT was associated with therapy failure and iv) an elevated EV concentration post-NACT was associated with a reduced three-year progression-free and overall survival. Of note, residual stem cell-like and/or resistant CTCs after therapy were associated with a lower EV concentration post-NACT. Our study highlights that the concentration of EVs within BC blood samples may serve as a complementary parameter reflecting the status of MRD as well as therapy and disease outcome in parallel with CTC investigation.